MORRISVILLE, N.C.--(BUSINESS WIRE)--etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of adaptive eClinical software and services designed to optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint, today announced that on May 18, 2009 it received a notice from the Nasdaq Stock Market indicating that it no longer complies with the requirements of Nasdaq Marketplace Rule 5450(b)(1)(A) for continued listing on the Nasdaq Global Market. The rule requires that etrials maintain minimum stockholders’ equity of $10,000,000. As reported in etrials’ quarterly report on Form 10-Q for the three months ended March 31, 2009, etrials’ stockholders’ equity was $9, 626,348 as of March 31, 2009.
